DMC Inhaler
for Anaphylaxis
At DMC we think differently about emergency drug delivery.
Our first-generation device aims to treat anaphylaxis by delivering epinephrine through inhalation.
The technology will utilise the pulmonary pathway to deliver life-saving medication. The large surface area of the lungs allows medications to be rapidly absorbed into the blood stream.
DEVELOPING EMERGENCY SOLUTIONS INTENDED FOR THE IMMEDIATE TREATMENT OF LIFE THREATENING CONDITIONS
The inhaler aims to improve upon the current standard of care through design and development seeking to become:
- Needle-free, reducing fear or hesitation
- 8 times faster to reach Cmax than widely used auto injector*
- Intuitive and easy to use
- A convenient small sized device
- Having a long expiry with convenient storage requirements
* In Phase 1 clinical studies testing inhalation delivery of DMC’s proprietary epinephrine formulation, plasma epinephrine concentrations reached Cmax 8 times faster compared to a widely used autoinjector.
